Effect of fibrinogen on platelet reactivity measured by the VerifyNow P2Y12 assay

[1]  M. Price,et al.  Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. , 2015, European heart journal.

[2]  J. Bennett.  Regulation of integrins in platelets , 2015, Biopolymers.

[3]  K. Huber,et al.  How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer? , 2015, Thrombosis and Haemostasis.

[4]  Yun Gi Kim,et al.  Different Influences of Hematocrit on the Results of Two Point-Of-Care Platelet Function Tests, the VerifyNow Assay and Multiple Electrode Platelet Aggregometry , 2014, PloS one.

[5]  A. Pichard,et al.  Does baseline hematocrit influence the assays of on-treatment platelet reactivity to clopidogrel? , 2014, American heart journal.

[6]  E. Vicaut,et al.  High On-Treatment Platelet Reactivity as a Risk Factor for Secondary Prevention After Coronary Stent Revascularization: A Landmark Analysis of the ARCTIC Study , 2014, Circulation.

[7]  J. Rade,et al.  Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness , 2013, Journal of thrombosis and haemostasis : JTH.

[8]  Peter L Duffy,et al.  Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.

[9]  E. Mahmud,et al.  Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. , 2013, Journal of the American College of Cardiology.

[10]  M. Cattaneo,et al.  Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution? , 2012, Journal of thrombosis and haemostasis : JTH.

[11]  P. Teirstein,et al.  Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay Impact on Thrombosis and Safety (GRAVITAS) Trial , 2011, Circulation.

[12]  M. Ruda,et al.  Glycoprotein IIb-IIIa content and platelet aggregation in healthy volunteers and patients with acute coronary syndrome , 2011, Platelets.

[13]  E. Mahmud,et al.  Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. , 2008, Journal of the American College of Cardiology.

[14]  E. Mahmud,et al.  Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention. , 2007, Journal of the American College of Cardiology.

[15]  H Tunstall-Pedoe,et al.  Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. , 2005, JAMA.

[16]  W. Wijns,et al.  The STIB score: a simple clinical test to predict clopidogrel resistance. , 2015, Acta cardiologica.

[17]  V. Fuster,et al.  The year in atherothrombosis. , 2013, Journal of the American College of Cardiology.

[18]  D. Atar,et al.  Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. , 2007, Thrombosis research.

[19]  Titov Vn,et al.  A simple method of isolating highly purified preparations of fibrinogen from human plasma , 1988 .